Hepatitis  	Hepatitis  	 NNP	B-NP
B 	B 	 NNP	I-NP
:  	:  	 :	O
clinical  	clinical  	 JJ	B-NP
application  	application  	 NN	I-NP
of  	of  	 IN	I-NP
HBsAg  	HBsAg  	 JJ	I-NP
quantification  	quantification  	 NN	I-NP
Since  	Since  	 IN	O
its  	its  	 PRP$	O
discovery  	discovery  	 NN	O
by  	by  	 IN	O
Blumberg  	Blumberg  	 NNP	O
in  	in  	 IN	O
1965 	1965 	 CD	O
,  	,  	 ,	O
hepatitis  	hepatitis  	 NNP	B-NP
B  	B  	 NNP	I-NP
virus  	virus  	 NN	I-NP
antigen  	antigen  	 NN	I-NP
( 	( 	 -LRB-	O
HBsAg 	HBsAg 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
used  	used  	 VBN	O
as  	as  	 IN	O
the  	the  	 DT	O
fingerprint  	fingerprint  	 NN	O
of  	of  	 IN	O
hepatitis  	hepatitis  	 NNP	B-NP
B  	B  	 NNP	I-NP
infection 	infection 	 NN	I-NP
.  	.  	 .	O
HBsAg  	HBsAg  	 JJ	B-NP
level  	level  	 NN	I-NP
reflects  	reflects  	 VBZ	O
the  	the  	 DT	O
transcriptional  	transcriptional  	 JJ	B-NP
activity  	activity  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
cccDNA 	cccDNA 	 JJ	O
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
an  	an  	 DT	O
important  	important  	 JJ	O
marker  	marker  	 NN	O
that  	that  	 WDT	O
might  	might  	 MD	O
not  	not  	 RB	O
only  	only  	 RB	O
indicate  	indicate  	 VB	O
active  	active  	 JJ	O
hepatitis  	hepatitis  	 NNP	B-NP
B  	B  	 NNP	I-NP
infection 	infection 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
may  	may  	 MD	O
also  	also  	 RB	O
predict  	predict  	 VB	O
clinical  	clinical  	 JJ	O
and  	and  	 CC	O
treatment  	treatment  	 NN	B-NP
outcomes 	outcomes 	 NNS	I-NP
.  	.  	 .	O
Assays  	Assays  	 NNP	O
for  	for  	 IN	O
HBsAg  	HBsAg  	 JJ	B-NP
quantification  	quantification  	 NNS	I-NP
are  	are  	 VBP	O
fully  	fully  	 RB	O
automated  	automated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
high  	high  	 JJ	O
output  	output  	 NN	B-NP
capacity 	capacity 	 NN	I-NP
.  	.  	 .	O
HBsAg  	HBsAg  	 JJ	B-NP
titer  	titer  	 NN	I-NP
is  	is  	 VBZ	O
higher  	higher  	 JJR	O
in  	in  	 IN	O
HBe  	HBe  	 JJ	B-NP
antigen  	antigen  	 NN	I-NP
( 	( 	 -LRB-	O
HBeAg 	HBeAg 	 NNP	B-NP
)  	)  	 -RRB-	O
positive  	positive  	 JJ	B-NP
chronic  	chronic  	 JJ	I-NP
hepatitis  	hepatitis  	 NN	I-NP
B  	B  	 NN	I-NP
than  	than  	 IN	O
in  	in  	 IN	O
HBeAg  	HBeAg  	 JJ	B-NP
negative  	negative  	 JJ	I-NP
patients  	patients  	 NNS	I-NP
and  	and  	 CC	O
is  	is  	 VBZ	O
negatively  	negatively  	 RB	O
correlated  	correlated  	 VBN	O
with  	with  	 IN	O
liver  	liver  	 JJ	O
fibrosis  	fibrosis  	 NN	O
in  	in  	 IN	O
HBeAg  	HBeAg  	 JJ	B-NP
positive  	positive  	 JJ	I-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
HBeAg  	HBeAg  	 JJ	B-NP
negative  	negative  	 JJ	I-NP
chronic  	chronic  	 JJ	I-NP
hepatitis  	hepatitis  	 NNP	I-NP
B 	B 	 NNP	I-NP
,  	,  	 ,	O
an  	an  	 DT	O
HBsAg  	HBsAg  	 JJ	B-NP
level  	level  	 NN	I-NP
< 	< 	 SYM	O
1,000  	1,000  	 CD	O
IU 	IU 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
mL  	mL  	 NNP	I-NP
and  	and  	 CC	O
an  	an  	 DT	O
HBV  	HBV  	 NNP	B-NP
DNA  	DNA  	 NNP	I-NP
titer  	titer  	 VBD	O
< 	< 	 SYM	O
2,000  	2,000  	 CD	O
IU 	IU 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
mL  	mL  	 NNP	I-NP
allow  	allow  	 VB	O
the  	the  	 DT	O
accurate  	accurate  	 JJ	O
identification  	identification  	 NN	B-NP
of  	of  	 IN	I-NP
inactive  	inactive  	 JJ	I-NP
carriers 	carriers 	 NNS	I-NP
.  	.  	 .	O
On  	On  	 IN	O
pegylated-interferon  	pegylated-interferon  	 NNP	B-NP
( 	( 	 -LRB-	O
PEG-IFN 	PEG-IFN 	 NNP	B-NP
)  	)  	 -RRB-	O
treatment 	treatment 	 NN	O
,  	,  	 ,	O
HBsAg  	HBsAg  	 JJ	B-NP
quantification  	quantification  	 NN	I-NP
allows  	allows  	 VBZ	O
identifying 	identifying 	 VBG	O
,  	,  	 ,	O
as  	as  	 IN	O
early  	early  	 JJ	O
as  	as  	 IN	O
week  	week  	 NN	B-NP
12  	12  	 CD	O
PEG-IFN  	PEG-IFN  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
patients  	patients  	 NNS	O
that  	that  	 WDT	O
will  	will  	 MD	O
not  	not  	 RB	O
benefit  	benefit  	 VB	O
from  	from  	 IN	O
therapy  	therapy  	 NN	O
and  	and  	 CC	O
thus  	thus  	 RB	O
stop  	stop  	 VB	O
or  	or  	 CC	O
switch  	switch  	 VB	O
treatment  	treatment  	 NN	B-NP
week  	week  	 NN	I-NP
12  	12  	 CD	O
stopping  	stopping  	 JJ	O
rule 	rule 	 NN	O
.  	.  	 .	O
Genotype  	Genotype  	 NNP	B-NP
A  	A  	 NNP	O
and  	and  	 CC	O
D 	D 	 NNP	O
:  	:  	 :	O
stop  	stop  	 VB	O
at  	at  	 IN	O
week  	week  	 NN	B-NP
12  	12  	 CD	O
if  	if  	 IN	O
no  	no  	 DT	O
HBsAg  	HBsAg  	 JJ	B-NP
decrease 	decrease 	 NN	I-NP
;  	;  	 :	O
Genotype  	Genotype  	 NNP	B-NP
B  	B  	 NNP	I-NP
and  	and  	 CC	O
C 	C 	 NNP	O
:  	:  	 :	O
stop  	stop  	 VB	O
at  	at  	 IN	O
week  	week  	 NN	B-NP
12  	12  	 CD	O
if  	if  	 IN	O
titer  	titer  	 CD	B-NP
>  	>  	 CD	O
20,000  	20,000  	 CD	O
UI 	UI 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
mL 	mL 	 NNP	I-NP
.  	.  	 .	O
With  	With  	 IN	O
regards  	regards  	 VBG	O
to  	to  	 TO	O
nucleos 	nucleos 	 VB	O
[ 	[ 	 -LRB-	O
t 	t 	 LS	O
] 	] 	 -RRB-	O
ides  	ides  	 JJ	B-NP
analogues  	analogues  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
the  	the  	 DT	O
role  	role  	 NN	O
of  	of  	 IN	O
HBsAg  	HBsAg  	 JJ	B-NP
quantification  	quantification  	 NN	I-NP
remains  	remains  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
clarified 	clarified 	 VBN	O
.  	.  	 .	O
Several  	Several  	 JJ	O
studies  	studies  	 NNS	O
indicate  	indicate  	 VBP	O
that  	that  	 DT	O
baseline  	baseline  	 NN	B-NP
and  	and  	 CC	O
on-treatment  	on-treatment  	 JJ	B-NP
HBsAg  	HBsAg  	 JJ	I-NP
levels  	levels  	 NNS	I-NP
might  	might  	 MD	O
allow  	allow  	 VB	O
identifying  	identifying  	 VBG	B-NP
patients  	patients  	 NNS	I-NP
that  	that  	 WDT	O
can  	can  	 MD	O
end  	end  	 VB	O
up  	up  	 RP	O
with  	with  	 IN	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
no  	no  	 DT	O
subsequent  	subsequent  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
reactivation 	reactivation 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
clinical  	clinical  	 JJ	B-NP
practice 	practice 	 NN	I-NP
,  	,  	 ,	O
HBsAg  	HBsAg  	 JJ	B-NP
quantification  	quantification  	 NN	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
simple  	simple  	 JJ	O
and  	and  	 CC	O
reproducible  	reproducible  	 JJ	O
worthwhile  	worthwhile  	 JJ	O
tool  	tool  	 NN	O
that  	that  	 WDT	O
can  	can  	 MD	O
be  	be  	 VB	O
used  	used  	 VBN	O
in  	in  	 IN	O
association  	association  	 NN	O
with  	with  	 IN	O
HBV  	HBV  	 NNP	B-NP
DNA  	DNA  	 NNP	I-NP
to  	to  	 TO	O
classify  	classify  	 VB	O
patients  	patients  	 NNS	O
during  	during  	 IN	O
HBV  	HBV  	 NNP	B-NP
infection  	infection  	 NN	I-NP
and  	and  	 CC	O
to  	to  	 TO	O
monitor  	monitor  	 VB	O
therapy 	therapy 	 NN	O
.  	.  	 .	O
